Retrophin sells pediatric disease priority review voucher to Sanofi for $245mm
Retrophin Inc. sold its rare pediatric disease priority review voucher (PRV) to Sanofi for $245mm. Sanofi paid $150mm up front, and will make two equal payments of $47.5mm in 2016 and 2017.
- Drug Delivery
- Large Molecule
- Priority Review Voucher (PRV) Sale
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.